Mirtin (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine. It also antagonizes serotonin 5‑HT2 and 5‑HT3 receptors while enhancing 5‑HT1A activity, leading to a net increase in serotonergic transmission. Its strong H1‑receptor antagonism contributes to sedation and appetite stimulation.

The appropriate dose of Mirtin is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Physicians typically start with a low dose and may adjust upward as needed, but exact dosing regimens should always follow the prescriber’s instructions.

Safety data for mirtazapine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the uncertainties and consider alternative treatments if appropriate.

To order Mirtin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mirtin (mirtazapine) belongs to the NaSSA class, whereas many other antidepressants are selective serotonin reuptake inhibitors (SSRIs). Compared with SSRIs, mirtazapine often causes more sedation and weight gain but may be more effective for patients with insomnia or poor appetite. Both classes improve mood, but side‑effect profiles differ, influencing individual treatment choice.

Mirtin should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date indicated on the label.

Mirtin is administered orally. The tablet should be swallowed whole with a glass of water, preferably in the evening because of its sedative effect. Patients should follow the dosing schedule prescribed by their healthcare professional and should not crush or chew the tablet unless specifically instructed.

Serious risks include the development of agranulocytosis or severe neutropenia, emergence or worsening of suicidal thoughts, and serotonin syndrome when combined with other serotonergic agents. Patients should seek immediate medical attention if they experience fever, sore throat, unusual bleeding, severe mood changes, or symptoms such as agitation, rapid heart rate, or high fever.

Mirtin is contraindicated in individuals with known hypersensitivity to mirtazapine or any of its excipients, and in patients who have taken monoamine oxidase inhibitors (MAOIs) within the past 14 days. Caution is also advised for patients with severe hepatic impairment, uncontrolled hypertension, or a history of bipolar disorder where antidepressant use may trigger mania.